Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 7/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 7/20 | 0.56 |
| ▸ | CACNB1 | Q02641 | 7/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.56 |
| ▸ | CCR5 | P51681 | 10/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458722 | 1.00 | CACNA2D1 (0.56) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1G | |
| SCHEMBL4458717 | 1.00 | CACNA2D1 (0.56) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1G | |
| SCHEMBL4460215 | 0.91 | CCR5 (0.55) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1G | |
| SCHEMBL4460220 | 0.91 | CCR5 (0.55) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1G | |
| SCHEMBL4465801 | 0.91 | CCR5 (0.55) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1G | |
| SCHEMBL4460125 | 0.90 | CCR5 (0.58) | CACNA2D1CACNA1BCACNB1CACNA1CCCR5 | |
| SCHEMBL4473810 | 0.90 | CCR5 (0.58) | CACNA2D1CACNA1BCACNB1CACNA1CCCR5 | |
| SCHEMBL4460130 | 0.90 | CCR5 (0.58) | CACNA2D1CACNA1BCACNB1CACNA1CCCR5 | |
| SCHEMBL4475768 | 0.86 | CACNA2D1 (0.57) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1G | |
| SCHEMBL4475771 | 0.86 | CACNA2D1 (0.57) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | claimed |
| JP-2007518742-A | — | — | 2007-07-12 | — | — | JP | claimed |
| EP-1718633-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2006-11-08 | — | — | EP | claimed |
| WO-2005070919-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2005-08-04 | — | — | WO | claimed |
| US-20050165065-A1 | N-type calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2005-07-28 | — | — | US | claimed |
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | disclosed |
| EP-1718633-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005070919-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165065-A1 | N-type calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165065-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | CACNA2D1 40/4885CACNA1B 1/4885CACNB1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.